Videos
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
SureCore needle: Interim data show longer, less fragmented cores
4
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
5